US backs another Covid-19 booster
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Springworks seeks cancer win as a prelude to something bigger
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
J&J breathes some more life into plamotamab and CD28
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Merck & Co justifies paying up for Acceleron
But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.
Non-genetic amyloidosis lives again, thanks to Darzalex and Astra
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Dynavax in clover on Covid-19 vaccine data
Meanwhile long-term efficacy of the Pfizer and Moderna jabs largely holds up, though J&J’s data seems less convincing.
